Maze Therapeutics officer exercises 12,500 RSUs
Maze Therapeutics, Inc. (MAZE) reported that Chief Strategy and Business Officer Atul Dandekar exercised restricted stock units into common stock on September 1, 2026.
Rhea-AI Filing Summary
Maze Therapeutics, Inc. (MAZE) reported that Chief Strategy and Business Officer Atul Dandekar exercised restricted stock units into common stock on September 1, 2026. 12,500 restricted stock units converted into 12,500 shares of common stock at no cash exercise price, increasing his directly held common shares to 38,750. Each restricted stock unit represents a right to receive one share of common stock upon settlement and vests in two equal tranches on September 1, 2026 and September 1, 2027, subject to his continued service, with units either vesting or being cancelled and not expiring.
Positive
- None.
Negative
- None.
Insider Trade Summary
12,500 shares exercised/converted
Exercise
2 txns
Insider
Dandekar Atul
Role
CSBO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F1, F2, F3 | 12,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 12,500 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Units — 12,500 contracts (Direct);
Common Stock — 38,750 shares (Direct)
Footnotes (3)
- F1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
- F2. The award vested or vests as to 1/2 of the total award on September 1, 2026 and September 1, 2027, subject to the reporting person's continued service to the Issuer on each vesting date.
- F3. These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.
Key Figures
RSUs exercised: 12,500 restricted stock units
Common shares acquired: 12,500 shares of common stock
Common shares held after transaction: 38,750 shares of common stock
+2 more
5 metrics
RSUs exercised
12,500 restricted stock units
Exercised or converted into common stock on September 1, 2026
Common shares acquired
12,500 shares of common stock
Received upon settlement of restricted stock units on September 1, 2026
Common shares held after transaction
38,750 shares of common stock
Direct holdings of Atul Dandekar following the September 1, 2026 transactions
RSU vesting schedule
50% on September 1, 2026; 50% on September 1, 2027
Vesting of the restricted stock unit award, subject to continued service
Exercise price per share
$0.00 per share
Reported price for RSU conversion into common stock on September 1, 2026
Key Terms
Restricted Stock Units, contingent right, vesting date, continued service
4 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"represents a contingent right to receive one share of the Issuer's Common Stock"
vesting date financial
"subject to the reporting person's continued service to the Issuer on each vesting date"
continued service financial
"subject to the reporting person's continued service to the Issuer on each vesting date"
FAQ
What insider transaction did MAZE report for Atul Dandekar on this Form 4?
Maze Therapeutics reported that CSBO Atul Dandekar exercised 12,500 restricted stock units into 12,500 shares of common stock on September 1, 2026. This was recorded as an exercise or conversion of a derivative security, not as an open-market purchase or sale.
What happened to the 12,500 restricted stock units in the MAZE Form 4?
The 12,500 restricted stock units were shown as a derivative position that was exercised or converted into 12,500 shares of common stock on September 1, 2026. The RSU entry is reported as disposed, while the common stock is reported as acquired.
How do the Maze Therapeutics (MAZE) RSUs reported for Atul Dandekar vest?
The award vests as to 1/2 of the total RSUs on September 1, 2026 and the remaining 1/2 on September 1, 2027, subject to Atul Dandekar’s continued service to Maze Therapeutics on each vesting date.
Do the restricted stock units reported by MAZE for Atul Dandekar have an expiration date?
The filing states that these restricted stock units do not expire. They either vest on their scheduled vesting dates or are cancelled prior to vesting; there is no separate expiration date beyond these vesting mechanics.
Was the MAZE insider transaction made under a Rule 10b5-1 trading plan?
The Form 4 indicates the Rule 10b5-1 plan checkbox as not affirmed (false). No footnote states that the September 1, 2026 transactions were executed pursuant to a Rule 10b5-1 trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
